Research in Your Backyard

PhRMA has created reports showcasing clinical trials in 25 states. These reports highlight the importance of clinical trials to patient health as well as the contribution to the local economy. The reports focus on clinical trials targeting six of the nation’s most debilitating diseases: asthma, cancer, diabetes, heart disease, mental illness and stroke. Click on any state name below to access a PDF of the full report for that state.

“We need to make more patients and doctors in South Carolina aware of local community clinical trials of new medicines. The fact is, we know that some chronic disease sufferers are still seeking treatments that are best for them and a clinical trial of a new drug, for some, could be a good therapeutic option to explore and discuss with their doctors. It’s important, very important, that nearly 300 trials of new chronic disease treatments in the state are still active and seeking patient recruits. Those trials include 178 tests of new cancer medicines, 31 tests of new diabetes drugs and 23 of new heart disease medications.” Paul Jeter, Executive Director, Leukemia & Lymphoma Society, South Carolina Chapter

“Clinical trials are a key research tool for advancing medical knowledge and patient care. They also are an economic driver, not only to the regions where they are performed, but also nationally and globally. Additionally, clinical trial results can help health care decision- makers direct resources to the strategies and treatments that work best and are safe. Patients from minority populations should be adequately represented in clinical trials since treatments affect a range of patient groups differently.” Russell E. Poland, Ph.D. Vice President for Research Professor, Department of Psychiatry, Meharry Medical College

"Freedom fuels innovation, and through our proud tradition of bold thinking and personal freedom, Texas is a natural fit for industries looking to create cutting-edge treatments, develop cures and improve lives. I’m proud of Texas’ ranking in clinical studies, and believe our state has the workforce, talent, universities and business climate to become a national leader for biotech research, development and commercialization." Governor Rick Perry

“Vermont is committed to good health for people, our environment, and our institutions including our schools, colleges and universities, our businesses and our cities and communities. One significant health care effort that doesn’t receive the attention it deserves is the active research activity of local research institutions—from Chittenden County to White River Junction, from Brattleboro to Bennington. Many of these institutions are members of the Vermont Biosciences Alliance. Working often in partnership with NIH and most major pharmaceutical companies, our research efforts are contributing to the development of life saving drugs, devices, and treatments. No one researcher or institution can single handedly develop a drug or a medical device. It requires capital, talent, drive, initiative and teamwork. Some of the things for which Vermont is known.” Bill Church, President of Green Mountain Antibodies; Chair, Vermont Biosciences Alliance (VBSA)

“The clinical trials biopharmaceutical companies have conducted in the Commonwealth have benefited not only patients, but also the state’s economy. They’ve been a boost to the economies of communities all over Virginia because the companies hire local research institutions —including university medical schools and community hospitals—to conduct the trials for them. And that has given these research centers an opportunity to be involved in challenging, cutting-edge science and a steady source of revenue.” Paul Miller, Chairman, Virginia Small Business Partnership

“Since cancer took the life of Gilda Radner, we’ve witnessed amazing advancements in cancer treatment. Clinical trials are an important part of making those advancements possible. Unfortunately, while nearly 20% of cancer patients are eligible for participation in cancer clinical trials, enrollment among adults consistently ranges between 3-5%. More must be done to unlock the incredible potential of clinical trials for patients with cancer and chronic illnesses.” Anna Gottlieb, Gilda’s Club Seattle

Biopharmaceutical companies’ close collaboration with clinicians and research institutions in West Virginia benefits patients, the state’s economy and the advance- ment of science and patient care. Clinical trial business is good business for the state’s medical schools and clinical research centers and the medicines being tested are often cutting-edge cell and protein treatments with the poten- tial to be safer and more effective than older chemical compound drugs. What’s more, West Virginians contemplating participation in clinical trials have a wide range of choices—nearly 40 tests of new medicines for the six most debilitating chronic diseases in America are underway in commu- nities large and small all over the state and they need patient volunteers. Additional clinical trials recruiting patients target other diseases such as rheumatoid arthritis, chronic obstructive pulmonary disease, traumatic brain injury, cystic fibrosis, influenza, lupus, and psoriasis.

“Clinical trials research is imperative for finding the next treatments and cures for costly chronic diseases and conditions. The 2012 cost for caring for individuals with Alzheimer’s disease in the U.S. is estimated at $200 billion. By 2050 costs are estimated to rise to $1.1 trillion (in today’s dollars) if a cure or more effective treatments are not found. We are privileged in Wisconsin to have some of the best research universities and facilities in the world working on this problem, including the Federal Alzheimer’s Disease Research Center located at the U.W. Madison.” Rob Gundermann, Public Policy Director, Alzheimer’s & Dementia Alliance of Wisconsin

Pages